Oncology Other denied as not FDA-approved for this use by Blue Cross Blue Shield?

For Anthem Blue Cross Blue Shield Marketplace (Individual & Commercial) members, oncology drugs administered under the medical benefit are delegated to Carelon Medical Benefits Management (formerly AIM Specialty Health) for prior authorization review. Carelon uses an evidence- and value-based approach utilizing cancer treatment pathways, provider-preferred clinical review, and enhanced reimbursement and pathway adherence reporting, covering approximately 85% of spending on cancer drugs across therapeutic and supportive drugs. Carelon Cancer Treatment Pathways are cancer treatment regimens intended to support quality cancer care and reduce unneeded variation in care and cost, developed through a rigorous process of integrating evidence-based literature with physician practice guidelines. Pathways identify a subset of regimens supported by clinical evidence and practice guidelines, selected based on clinical benefit (efficacy), safety/side effects (especially those leading to hospitalizations and impacting quality of life), strength of national guideline recommendations, and cost of regimens. Off-pathway requests are reviewed individually: the platform approves requests that align with policy and pathways, and board-certified medical oncologists and nurses consult on off-pathway requests and alert providers to enhanced reimbursement opportunities. For some health plans, requested services are reviewed in accordance with client medical policies and clinical guidelines; if a request is received that is not a Carelon Pathway regimen, it may be reviewed and authorized if determined to be medically necessary, with reference to NCCN Clinical Practice Guidelines in Oncology. Critical elements include confirming the diagnosis based on a complete evaluation including history, physical examination, relevant laboratory studies, diagnostic testing, and response to prior therapeutic intervention, with anticipated benefit outweighing potential harms. Self-administered/oral oncology drugs under the pharmacy benefit are reviewed against CarelonRx clinical criteria approved by the CarelonRx Pharmacy and Therapeutics Committee, an independent external committee of practicing physicians, pharmacists, and clinicians from leading academic medical centers with expertise in evidence-based medicine across all major clinical specialties.

- Carelon's own framework permits off-pathway approval when medically necessary: the treating oncologist determines if a Pathway regimen is the best option or whether, given the patient's unique circumstances, another regimen is a better choice, and non-Pathway requests may be authorized if determined to be medically necessary, referencing NCCN Clinical Practice Guidelines in Oncology. - Cite the specific NCCN Clinical Practice Guideline (Category 1 or 2A recommendation) supporting the requested regimen for the patient's histology, stage, and biomarker status — Carelon explicitly references NCCN as an authoritative source for medical necessity determinations. - Submit biomarker/pathology reports (e.g., NGS, IHC, FISH) confirming the targetable alteration required by the FDA label or NCCN guideline; Carelon requires confirmation of the diagnosis based on complete evaluation including review of relevant laboratory studies and diagnostic testing. - For step-therapy denials, document contraindication, intolerance, or prior failure of preferred agents; step therapy requires that the member has tried an alternative therapy first, or that the prescriber has clinically documented why the member cannot take the alternative therapy. - Demonstrate that benefit outweighs harm and delay would worsen outcomes: the anticipated benefit of the recommended intervention is likely to outweigh any potential harms, including from delay or decreased access to treatment. - Invoke clinician authority and individualization: medical necessity decisions may change as new information is provided or based on unique aspects of the patient's condition, and the treating clinician has final authority and responsibility for treatment decisions and for justifying medical necessity. - For Marketplace ACA plans, cite the ACA's essential health benefit protections and the plan's obligation to follow recognized compendia (NCCN Drugs & Biologics Compendium, AHFS, Micromedex DrugDex) for off-label oncology indications, which Carelon's pathway framework already incorporates via NCCN alignment.

## Why BCBS May Deny an Oncology Drug as "Not FDA-Approved" and How to Appeal

Blue Cross Blue Shield may issue a "not FDA-approved" denial in oncology for several reasons: the drug may be used in an off-label indication (an FDA-approved drug prescribed for a use not listed on its label), the specific combination may not have a dedicated FDA approval, or there may be a plan-side administrative error in categorizing the drug's approval status. Off-label oncology use is extremely common and is explicitly recognized as medically appropriate under federal policy when supported by recognized clinical evidence.

### Why This Denial Is Appealable

Federal law and most state insurance codes recognize that oncology drugs used off-label can still be covered when the use is supported by recognized oncology compendia or clinical guidelines. Many BCBS plans are contractually required to cover off-label oncology use supported by compendium listing. If the drug has any FDA approval and is being used off-label, your appeal should focus on compendium support and guideline concordance — not on trying to obtain a new FDA approval.

### Federal Appeal Framework

• Internal appeal: File within the timeframe stated on your denial notice. ERISA §503 full-and-fair review entitles you to submit evidence including FDA approval status, compendium listings, and your oncologist's clinical rationale.
• External review (ACA §2719): After exhausting internal appeals, you may request independent external review within four months of the final internal denial. Reviewers are required to apply current clinical guidelines.
• Expedited option: If treatment delay would harm your health, request expedited review. Expedited external review typically resolves within 72 hours.

### Documentation to Gather

1. FDA approval status documentation: The current FDA prescribing label showing approval status for any indication. If the use is off-label, note that the drug holds FDA approval for at least one indication. 2. Compendium listing: Your oncologist should confirm whether the specific off-label use is listed in a recognized oncology drug compendium (such as the NCCN Drugs and Biologics Compendium), which most BCBS plans are required to cover. 3. Oncologist medical-necessity letter: A letter explaining the clinical basis for the off-label use, referencing the applicable guideline organization and compendium listing. 4. Diagnosis and biomarker records: Documentation that establishes the specific clinical indication — demonstrating why this drug is the appropriate choice for your cancer type and profile. 5. BCBS off-label coverage policy: Request the plan's written policy on off-label oncology coverage so you can address each criterion.

### Criteria-Mapping Approach

| Plan's Coverage Basis | Your Appeal Evidence | |---|---| | FDA approval status | [Label documentation; note any on-label approval] | | Compendium support for off-label use | [Compendium listing confirmed by oncologist] | | Guideline concordance | [Oncologist letter citing guideline organization] | | Medical necessity for this indication | [Diagnosis, biomarker, and staging records] |

Off-label oncology denials are among the most-reversed on external review when the compendium listing and guideline support are clearly documented — these are the exact standards that independent reviewers are required to apply.